DJ Carvolix joins key Euronext indices, marking a new milestone in its capital markets profile.
Affluent Medical
Carvolix joins key Euronext indices, marking a new milestone in its capital markets profile.
23-March-2026 / 17:45 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Carvolix joins key Euronext indices, marking a new milestone in its capital markets profile
Aix-en-Provence, March 23, 2026 - 5:45 pm. CET - Carvolix (formerly Affluent Medical) (ISIN: FR0013333077 - Ticker: CVX
- "Carvolix" or the "Company"), a French commercial and clinical-stage medical technology company specializing in the
international development and industrialization of breakthrough AI-driven mini-robots and biomimetic implants,
announces its inclusion in the CAC Small, CAC Mid & Small and CAC All-Tradable indices, following the latest
quarterly review by Euronext.
This decision is effective as of March 23, 2026. This inclusion is expected to enhance the Company's visibility,
improve trading liquidity and broaden its investor base, notably through increased exposure to index-tracking funds.
Sébastien Ladet, CEO comments: "Our inclusion in these Euronext indices marks a milestone in Carvolix's development. It
reflects the growing recognition of our technology platform and strengthens our visibility among institutional
investors. This step supports our ambition to accelerate the deployment of our AI driven mini robotic solutions to
democratize access to complex procedure in structural heart diseases and stroke."
About Carvolix
Carvolix is a French medical technologies company, commercial and clinical stage, founded by Truffle Capital, that aims
to become a global leader in the treatment of structural heart diseases and brain strokes, world's leading causes of
mortality and disability. Carvolix develops novel AI and imaging driven mini robots that make complex procedures doable
by interventional cardiologists, as well as biomimetics heart valves.
Contacts:
CARVOLIX SEITOSEI.ACTIFIN
Financial communication / Financial press relations
Sébastien Ladet Ghislaine GASPARETTO / Enora BUDET
CEO +33 (0)6 85 36 76 81 / +33 (0)6 02 08 45 49
investor@carvolix.eu ghislaine.gasparetto@seitosei-actifin.com / jennifer.jullia@seitosei-actifin.com
MC SERVICES AG
PRIMATICE
Media relations Europe
Media relations France
Thomas Roborel de Climens Maximilian SCHUR / Julia BITTNER
+33 (0)6 78 12 97 95
+49 (0)211 529252 20 / +49 (0)211 529252 28
thomasdeclimens@primatice.com
carvolix@mc-services.eu
----------------------------------------------------------------------------------------------------------------------- Regulatory filing PDF file
File: 20260323_PR_CARVOLIX_Euronext index integration
=------------------------------------------------------------------
Language: English
Company: Affluent Medical
320 avenue Archimède, Les pléiades III Bâtiment B
13100 Aix en Provence France
France
Phone: +33 4 42 95 12 20
E-mail: jerome.geoffroy@affluentmedical.com
Internet: https://www.affluentmedical.com/
ISIN: FR0013333077
Euronext Ticker: AFME
AMF Category: Inside information / Other releases
EQS News ID: 2296178
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
2296178 23-March-2026 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2296178&application_name=news&site_id=dow_jones%7e%7e%7ebed8b539-0373-42bd-8d0e-f3efeec9bbed
(END) Dow Jones Newswires
March 23, 2026 12:45 ET (16:45 GMT)
© 2026 Dow Jones News
